crizanlizumab
novartis
['spartan', 'crizanlizumab']
53% median reduction (iqr -73 to +9) in priapic events at 26 weeks with crizanlizumab in 24 patients anderson a, et al. interim analysis of a phase 2 trial to assess the efficacy and safety of crizanlizumab in #sicklecell with #priapism (spartan) at #eha23 
blood doctor finding new treatments for#Thalassemia #SickleCell #PKdeficiency #HS #HE/#HPP #CDA #G6PD, @UofT_DoM @ihpmeuoft also @MSF Tweets are my own